Market Overview

Alnylam, Tekmira Resolve All Litigation; Alnylam to Make $65M One-Time Payment

Share:
Related ALNY
Alnylam Initiates Phase 3 Open Label Extension Study with Patisiran, an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR Amyloidosis)
5 Biotech Stocks On Deck With The FDA
Related TKMR
Tekmira Officially Becomes Arbutus Biopharma
Sierra Leone's Freetown Set Back In Ebola Eradication

Alnylam (NASDAQ: ALNY) and Tekmira Pharma (NASDAQ: TKMR) announced a settlement agreement that resolves all litigation between the companies, and has signed a new licensing agreement that restructures the relationship and provides clarity on all intellectual property and licensing issues between the companies. As a result of the restructuring and new agreements, Tekmira will receive $65 million within 10 days and is eligible to receive $10 million in near-term milestone payments expected to be received in 2013.

Posted-In: News Legal

 

Related Articles (ALNY + TKMR)

Get Benzinga's Newsletters